Invion

Invion Current Assets

The Current Assets of Invion (IVX.AX) as of Oct 10, 2026 is 697,444.00 AUD. In the previous year, Current Assets was 933,203.00 AUD — a change of -25.26% (lower).

Current Assets

697,444.00AUD

YoY

-25.26%

Last updated:

Current Assets of Invion is 2026 697,444.00 AUD. Current Assets of Invion was 2025 933,203.00 AUD. It decreases by -25.26% lower compared to the previous year.

The Invion Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
1.03 M AUD
Jan 1, 2020
916,816.00 AUD
Jan 1, 2021
1.08 M AUD
Jan 1, 2022
8.65 M AUD
Jan 1, 2023
4.14 M AUD
Jan 1, 2024
-339,629.00 AUD
Jan 1, 2025
933,203.00 AUD
Jan 1, 2026
697,444.00 AUD
The Invion Current Assets history
YEARCurrent AssetsYoY
697,444.00AUD-25.26%
933,203.00AUD-374.77%
-339,629.00AUD-108.19%
4.14 MAUD-52.07%
8.65 MAUD+703.58%
1.08 MAUD+17.38%
916,816.00AUD-11.33%
1.03 MAUD-65.18%
2.97 MAUD+204.67%
974,490.00AUD+87.72%
519,132.00AUD+3.80%
500,120.00AUD-85.43%
3.43 MAUD-26.43%
4.66 MAUD-27.87%
6.47 MAUD+51.11%
4.28 MAUD+13.68%
3.76 MAUD-84.12%
23.71 MAUD+890.98%
2.39 MAUD-9.63%
2.65 MAUD+14.34%
2.32 MAUD+4,187.33%
54,000.00AUD—
0.00AUD-100.00%
32,000.00AUD+68.42%
19,000.00AUD—
0.00AUD—
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Current Assets of Invion is 697,444.00 AUD in 2026.

Current Assets of Invion changed from 933,203.00 AUD to 697,444.00 AUD, representing a -25.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Invion since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Invion historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Invion

All Key Metrics — Invion